Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 64-70

  Bos, A M E ^a   Boom, K ^a   Vinks, A A ^b   Boezen, H M ^c   Wanders, J ^d   Dombernovsky, P ^e   Aamdal, S ^f   De Vries, E G E ^a   Uges, D R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d NDDO Oncology   (Netherlands)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anthracycline; MEN 10755; Optimal sampling strategy; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; SABARUBICIN;

ADULT; ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; MATHEMATICAL COMPUTING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; SOLID TUMOR;

ALGORITHMS; BAYES THEOREM; DISACCHARIDES; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SPECIMEN HANDLING; TIME FACTORS;

EID: 3042728676     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0772-7     Document Type: Article

References (42)

1. Akaike H (1976) An information criterion. Math Sci 14:59
2. Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R, Zunino F (1997) Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst 89:1217-1223
3. Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 48:361-369
4. Canal P, Chatelut E, Guichard S (1998) Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56:1019-1038
5. Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renee N, Milano G, Canal P (2000) A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 36:264-269
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
7. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73-80
8. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739-756
9. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134
10. D'Argenio D, Schumitzky A (1992) ADAPT II users guide. Biomedical Simulations Resource, University of Southern California, Los Angeles
11. Drusano GL (1991) Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination. J Clin Pharmacol 31:962-967
12. Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known, 1916. Nutrition 5:303-311
13. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49:3129-3133
14. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23:1083-1087
15. Evans WE, Relling MV (1989) Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327-336
16. Hon YY, Evans WE (1998) Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 44:388-400
17. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54 [Suppl 4]:1-7
18. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J (1991) Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 21:461-478
19. Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, Gomis P, Barbaut X, Tahani B (1993) Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 15:380-393
20. Jelliffe R, Schumitzky A, Van Guilder M (1994) User manual for version 10.1 of the USC*PACK collection of PC programs. Laboratory of Applied Pharmacokinetics, University of Southern California, School of Medicine, Los Angeles
21. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528
22. Jodrell DI, Murray LS, Hawtof J, Graham MA, Egorin MJ (1996) A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 37:356-362
23. Launay MC, Milano G, Iliadis A, Frenay M, Namer N (1989) A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 60:89-92
24. Masson E, Zamboni WC (1997) Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 32:324-343
25. Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019
26. Minami H, Beijnen JH, Verweij J, Ratain MJ (1996) Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res 2:43-46
27. Miyazaki M, Fujiwara Y, Takahashi T, Isobe T, Ohune T, Tsuya T, Yamakido M (1997) Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 17:4571-4575
28. Moore MJ, Erlichman C (1987) Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet 13:205-227
29. Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, Salvatore C, Casazza A, Arcamone F, Zunino F (1998) Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clin Cancer Res 4:2833-2839
30. Proost JH, Meijer DK (1992) MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22:155-163
31. Ranson MR, Scarffe JH (1994) Population and Bayesian pharmacokinetics in oncology. Clin Oncol (R Coll Radiol) 6:254-260
32. Ratain MJ, Robert J, van der Vijgh WJ (1991) Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 9:871-876
33. Rousseau A, Marquet P, Debord J, Sabot C, Lachatre G (2000) Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 38:315-353
34. Schrijvers D, Bos AME, Dyck J, de Vries EGE, Wanders J, Roelvink M, Fumoleau P, Bortini S, Vermorken JB (2002) A phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 13:385-391
35. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
36. Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324-327
37. Steimer J, Mallet A, Mentre F (1985) Estimating interindividual pharmacokinetic variability. Variability in drug therapy: description, estimation and control. Raven Press, New York, pp 65-109
38. Stromgren AS, Sorensen BT, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 32:226-230
39. Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, Trillet-Lenoir V, Canal P, Lochon I, Ardiet CJ (1999) A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 43:316-322
40. van Warmerdam LJ, Bokkel Huinink WW, Maes RA, Beijnen JH (1994) Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120:427-433
41. Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W (1996) Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 40:1091-1097
42. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670-686